Valuation : Novavax, Inc.

Market Cap 1.69B 1.45B 1.36B 1.24B 2.33B 159B 2.34B 16.17B 6.25B 81.64B 6.33B 6.19B 260B P/E 2026 *
-16.4x
P/E 2027 * -45.6x
Enterprise Value 1.9B 1.64B 1.54B 1.41B 2.63B 180B 2.64B 18.27B 7.06B 92.25B 7.15B 7B 294B EV / Sales 2026 *
5.11x
EV / Sales 2027 * 7.47x
Free-Float
93.05%
Yield 2026 *
-
Yield 2027 * -
1 day-1.16%
1 week+10.37%
Current month+9.07%
1 month+32.04%
3 months+7.69%
6 months+2.40%
Current year+52.08%
1 week 9.19
Extreme 9.19
10.75
1 month 7.7
Extreme 7.695
10.75
Current year 6.76
Extreme 6.76
11.97
1 year 6.2
Extreme 6.2
11.97
3 years 3.53
Extreme 3.5324
23.86
5 years 3.53
Extreme 3.5324
277.8
10 years 3.53
Extreme 3.5324
331.68
Manager TitleAgeSince
Chief Executive Officer 59 2023-01-22
Director of Finance/CFO 60 2021-08-15
Chief Tech/Sci/R&D Officer - 2021-12-31
Director TitleAgeSince
Director/Board Member 73 2010-08-05
Director/Board Member 66 2018-10-31
Director/Board Member 60 2020-06-15
Date Insider Type Main position Quantity % Market Cap. Importance
6/20/26 Exercice

Director

37,760 0.0230%
6/18/26 Free

Director

35,450 0.0216%
4/25/26 Exercice

Director

19,040 0.0117%
Change 5-day change 1-year change 3-year change Capi.($)
-1.16%+10.37%+29.37%+4.93% 1.69B
-1.16%-2.77%-1.68%+13.85% 48.93B
-0.40%+1.03%+418.57%+527.30% 45.01B
-1.42%+2.30%+42.67%+22.37% 44.07B
-1.22%-2.31%+4.82%+77.49% 40.73B
-0.96%-2.31%+15.75%+45.41% 33.52B
-0.21%+9.14% - - 17.77B
-0.35%-1.56%+21.42%+120.75% 16.5B
-1.54%-1.30%+12.02%+31.14% 14.67B
-1.65%-1.03%+75.93%+41.12% 13.77B
Average -0.98%+1.47%+68.76%+98.26% 27.67B
Weighted average by Cap. -0.95%+0.11%+88.79%+127.86%

Financials

2026 *2027 *
Net sales 373M 321M 302M 275M 515M 35.27B 517M 3.58B 1.38B 18.06B 1.4B 1.37B 57.53B 266M 229M 215M 197M 368M 25.17B 369M 2.55B 987M 12.89B 1B 978M 41.06B
Net income -108M -92.49M -86.99M -79.41M -149M -10.17B -149M -1.03B -399M -5.21B -404M -395M -16.59B -37.93M -32.62M -30.68M -28M -52.38M -3.59B -52.54M -364M -141M -1.84B -142M -139M -5.85B
Net Debt 219M 188M 177M 162M 302M 20.71B 303M 2.1B 812M 10.61B 822M 804M 33.78B 303M 261M 245M 224M 419M 28.68B 420M 2.91B 1.12B 14.69B 1.14B 1.11B 46.78B
Logo Novavax, Inc.
Novavax, Inc. is a biotechnology company. It is focused on addressing global health challenges through its vaccines and its proven technology platform, including protein-based nanoparticles and its Matrix-M adjuvant. Matrix-M can be used to create vaccines for a variety of diseases to help tackle some of the pressing health challenges. Its proprietary Matrix-M adjuvant, when added to vaccines, has been shown to help induce a stronger and longer-lasting immune response. Its recombinant protein-based nanoparticle technology has been shown to be highly immunogenetic. Its technology platform is used in its authorized COVID-19 vaccine and the R21/Matrix-M adjuvant malaria vaccine. Its late-stage programs include a COVID-19-Influenzavaccine candidate, and an influenza vaccine candidate. R21/Matrix-M adjuvant malaria vaccine, a malaria vaccine developed by its partner. It provides Matrix-M adjuvant for use in various programs in preclinical and clinical stage, and preclinical investigations.
Employees
749
Date Price Change Volume
26-09-04 US$10.22 -1.16% 5,125,027
26-09-03 US$10.34 +0.19% 6,226,630
26-09-02 US$10.32 +1.98% 5,635,817
26-09-01 US$10.12 +8.00% 10,040,575
26-08-31 US$9.370 +1.19% 7,271,750
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
BB
Sell
Consensus
Buy
Mean consensus
OUTPERFORM
Number of Analysts
9
Last Close Price
10.22USD
Average target price
14.00USD
Spread / Average Target
+37.01%

Quarterly revenue - Rate of surprise

  1. Stock Market
  2. Stocks
  3. NVAX Stock
40% Discount: Identify Tomorrow's Best Investments With The Best Subscriber-Only Tools!
d
:
:
SEIZE THE OFFER!